

**Aus der Medizinischen Universitätsklinik und Poliklinik  
(Department) Tübingen  
Abteilung Innere Medizin II  
Ärztlicher Direktor: Professor Dr. L. Kanz  
Sektion für Transplantationsimmunologie und Immunhämatologie  
Zentrum für Medizinische Forschung  
Leiterin: Professor Dr. C. Müller**

**Immunogenicity of the HO-1 Peptide eluted from  
Renal Cell Carcinoma for CD8 T cells**

**Inaugural-Dissertation  
Zur Erlangung des Doktorgrades  
der Medizin**

**der Medizinischen Fakultät  
der Eberhard-Karls-Universität  
zu Tübingen**

**vorgelegt von  
Veneta Hristova Grigorova  
aus  
Sofia/Bulgarien**

**2010**

Dekan: Professor Dr. I. B. Autenrieth

1. Berichterstatter: Professor Dr. G. Pawelec
2. Berichterstatter: Professor Dr. S. Stevanović

## **ACKNOWLEDGEMENTS**

I would like to thank the following people for their help and support during my stay in Tübingen:

Professor Dr. Graham Pawelec at the University of Tübingen for accepting me into his group, for his scientific input and assistance, for being an excellent supervisor and for his useful advice and comments.

Dr. Ludmila Mueller for being a good teacher and friend. Her advice during the practical work was always useful.

Ashley Knights and Evelyn Derhovanessian both for their help in my practical work and being good friends and teachers.

The people of the TATI group, past and present, especially Karin Hähnel and Arnika Rehbein as well as other groups (especially Jon Tolson) who were always friendly and willing to help.

Last but not least, I would like to thank all the members of my family, especially my mother, for their financial and emotional support, as well as my close friends for their constant support.

## **Contents**

### **1. Introduction**

|         |  |    |
|---------|--|----|
| 1.1     | Immune response to cancer                            | 1  |
| 1.1.1   | Innate Immunity                                      | 2  |
| 1.1.2   | Adaptive Immunity                                    | 4  |
| 1.1.2.1 | Antigen presentation/processing                      | 4  |
| 1.1.2.2 | MHC Class I-restricted immunity                      | 6  |
| 1.1.2.3 | Cross-presentation                                   | 7  |
| 1.1.3   | Tumour antigens                                      | 10 |
| 1.1.4   | Techniques for the identification of tumour antigens | 12 |
| 1.1.5   | Reverse immunology                                   | 15 |
| 1.1.6   | Manipulating the immune response                     | 15 |
| 1.2     | Renal cell cancer                                    | 17 |

### **2. Material and Methods**

|        |  |    |
|--------|--|----|
| 2.1.   | Isolation of PBMC                                      | 20 |
| 2.2.   | HLA typing   | 20 |
| 2.3.   | Synthetic peptides                                     | 21 |
| 2.4.   | Cultivation of cell lines                              | 21 |
| 2.4.1. | Quantification of cell number and viability            | 22 |
| 2.4.2. | Cryopreservation of cells                              | 22 |
| 2.5.   | Dendritic cell generation                              | 23 |
| 2.6.   | Generation of T cell lines                             | 24 |
| 2.6.1. | Cytokine-modified bulk-culture protocol                | 24 |
| 2.6.2. | Dendritic cell sensitisation                           | 24 |
| 2.7.   | Inactivation of cells used as antigen presenting cells | 25 |
| 2.8.   | Enzyme-linked immunosorbent assay (ELISA)              | 25 |
| 2.9.   | IFN- $\gamma$ ELISpot assay                            | 26 |
| 2.10.  | Effector-cell degranulation assay                      | 27 |

### **3. Results**

|     |  |    |
|-----|--|----|
| 3.1 | Generation of specific T-cell lines from PBMC of healthy donor, using synthetic HO-I peptide | 28 |
| 3.2 | Screening the established T-cell lines for HO-1 specific                                     |    |

|            |  |           |
|------------|--|-----------|
|            | cytokine release by ELISA  | 29        |
| 3.3        | Measurement of antigen-specific IFN- $\gamma$ production by T lymphocytes at the single cell level by ELISpot assay          | 30        |
| 3.4        | Evaluation of antigen-specific cytolytic activity of the generated peptide-specific T-cell line by CD107a mobilisation assay | 36        |
| <b>4.</b>  | <b>Discussion</b>  | <b>40</b> |
| <b>5.</b>  | <b>Abstract</b>  | <b>52</b> |
| <b>6.</b>  | <b>Zusammenfassung</b>   | <b>54</b> |
| <b>7.</b>  | <b>List of abbreviations</b>   | <b>56</b> |
| <b>8.</b>  | <b>Reference List</b>  | <b>58</b> |
| <b>9.</b>  | <b>Reference List – Alphabetic order</b>   | <b>68</b> |
| <b>10.</b> | <b>CV (Lebenslauf)</b>   | <b>79</b> |